))
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Manage episode 433877199 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 1.00
Valid until: 08-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/enhancing-treatment-strategies-with-molecular-approaches-in-her2-gastrointestinal-cancers/18134/
Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC with HER2-directed therapies. The symposium also covers the role of genomic profiling in guiding treatment decisions for HER2+ BTC and emphasizes the importance of interprofessional collaboration in managing adverse events associated with HER2-directed therapies in patients with GI cancer. =
…
continue reading
Valid until: 08-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/enhancing-treatment-strategies-with-molecular-approaches-in-her2-gastrointestinal-cancers/18134/
Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC with HER2-directed therapies. The symposium also covers the role of genomic profiling in guiding treatment decisions for HER2+ BTC and emphasizes the importance of interprofessional collaboration in managing adverse events associated with HER2-directed therapies in patients with GI cancer. =
568 episodes
Share
